TNF Blockers May Trigger Demyelinating Disease

BY BRUCE K. DIXON
Chicago Bureau

CLEVELAND — Treatment with a tumor necrosis factor-α inhibitor may trigger a demyelinating polyneuropathy with Guillain-Barré-like symptoms, according to MaryAnn Mays, M.D., of the Cleveland Clinic Foundation.

The case, in point, presented in a poster at a symposium on the treatment of autoimmune and inflammatory disorders

sponsored by the clinic, was that of a 56-year-old man with seropositive rheumatoid arthritis who became severely disabled after infliximab infusions were added to methotrexate.

Dr. Mays, a neurologist, reported in an interview that the patient’s rheumatoid arthritis symptoms lessened markedly following his first antitumor necrosis factor treatment in 2002, but following an infusion in late 2003, he experienced dizziness and hearing loss that lasted for a week. The symptoms recurred and lasted longer following a third infusion 2 months later.

The next infliximab infusion in April 2004 produced worsening neurologic symptoms, including blurred vision, headaches, dysarthria, hearing loss, ataxia, dysphagia requiring percutaneous endoscopic gastrostomy for nutrition, and progressive weakness, Dr. Mays said.

Initial evaluation included cerebrospinal fluid WBC of 123, protein 79, and electromyogram consistent with demyelinating polyneuropathy. But the overall pattern was not typical of Guillain-Barré syndrome [GBS]. Dr. Mays said. “He had high white count and normal protein. Auditory evoked potentials showed a right central conduction disturbance. His de- trusor urinary muscle did not respond to stimuli, which is typical of GBS. His right Babinski sign was atypical of GBS.”

Feyrouz Al-Ashtar, M.D., the lead investigator and a rheumatologist, noted in an interview that by the time the patient was brought to the clinic, he “could not walk, use his hands, lift his head, or feed himself, although he could still breathe on his own.”

He received intravenous immunoglobulin and steroids before we saw him. When he got here, he again received intravenous steroids and another course of intravenous immunoglobulin, and slowly, but surely, he recovered completely,” Dr. Al-Ashtar said.

Dr. Mays noted “the fact that the patient responded to this course of intravenous immunoglobulin was further evidence that what he had was a demyelinating polyneuropathy other than GBS.”

According to Dr. Al-Ashtar, the message to clinicians “is that if you start noticing neurologic deficits or other adverse events, especially demyelinating diseases, in patients who are receiving infliximab, this should alert you to stop it and look for another treatment.”

Dr. Al-Ashtar wrote that “if neurologic symptoms occur following [TNF] infu- sion, then evaluation for demyelinating disease, including chronic inflammatory demyelinating polyneuropathy, multiple sclerosis, and GBS, should be pursued.”

“In such cases, our experience would suggest that there is potential for worsening of neurologic deficits with each infliximab treatment, and that continuing treatments after onset of neurologic symptoms would be relatively contraindicated,” she wrote.

Dr. Mays, a neurologist, reported in an interview that the patient’s rheumatoid arthritis symptoms lessened markedly following his first antitumor necrosis factor treatment in 2002, but following an infusion in late 2003, he experienced dizziness and hearing loss that lasted for a week. The symptoms recurred and lasted longer following a third infusion 2 months later.

The next infliximab infusion in April 2004 produced worsening neurologic symptoms, including blurred vision, headaches, dysarthria, hearing loss, ataxia, dysphagia requiring percutaneous endoscopic gastrostomy for nutrition, and progressive weakness, Dr. Mays said.

Initial evaluation included cerebrospinal fluid WBC of 123, protein 79, and electromyogram consistent with demyelinating polyneuropathy. But the overall pattern was not typical of Guillain-Barré syndrome [GBS]. Dr. Mays said. “He had high white count and normal protein. Auditory evoked potentials showed a right central conduction disturbance. His de- trusor urinary muscle did not respond to stimuli, which is typical of GBS. His right Babinski sign was atypical of GBS.”

Feyrouz Al-Ashtar, M.D., the lead investigator and a rheumatologist, noted in an interview that by the time the patient was brought to the clinic, he “could not walk, use his hands, lift his head, or feed himself, although he could still breathe on his own.”

He received intravenous immunoglobulin and steroids before we saw him. When he got here, he again received intravenous steroids and another course of intravenous immunoglobulin, and slowly, but surely, he recovered completely,” Dr. Al-Ashtar said.

Dr. Mays noted “the fact that the patient responded to this course of intravenous immunoglobulin was further evidence that what he had was a demyelinating polyneuropathy other than GBS.”

According to Dr. Al-Ashtar, the message to clinicians “is that if you start noticing neurologic deficits or other adverse events, especially demyelinating diseases, in patients who are receiving infliximab, this should alert you to stop it and look for another treatment.”

Dr. Al-Ashtar wrote that “if neurologic symptoms occur following [TNF] infu- sion, then evaluation for demyelinating disease, including chronic inflammatory demyelinating polyneuropathy, multiple sclerosis, and GBS, should be pursued.”

“In such cases, our experience would suggest that there is potential for worsening of neurologic deficits with each infliximab treatment, and that continuing treatments after onset of neurologic symptoms would be relatively contraindicated,” she wrote.